

Eastwood Bio-Medical Canada Inc.

Fact Sheet

www.eleotin.ca



Trading symbol:

TSX-V: EBM

Sector: Healthcare -
Biotechnology

Total Shares: 68,885,969

Investor Contact:

Eastwood Bio-Medical
Canada Inc.

Yunji Kim, President,

CEO and Director

Tel: 604-247-2100

Fax: 604-247-2101

Email:

info@eastwoodcos.com

Website:

www.eleotin.ca

Address:

1130 - 4871 Shell Road,

Richmond BC Canada

V6X 3Z6

Key Executives:

Yunji Kim

President, CEO and
Director

Peter Chen

CFO and Director

Dr. Terrance Owen, PhD
Director

Dr. Marcus Kuypers, MD
Director

Corporate Profile

The Company is a Vancouver based company whose Eleotin® brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.* Eleotin® was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on the cause, cure, and prevention of Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People's Republic of China. Eleotin® products have been endorsed by thousands of doctors and diabetes associations around the globe.*



Company Highlights

Eleotin® Bentley authorized to be marketed as "the World's No.1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product Available in Canada".*

Owens **68 Natural Product Numbers (NPN)** approved by Health Canada.

New **manufacturing capabilities** provide the best quality and process control.

Entered **binding terms** for Asian exports.

Since 1996 almost **500,000** individual unique customers worldwide have used Eleotin® products.

Production Facility Highlights

New manufacturing capabilities allow the Company to finally start producing highly advanced and complex products with the best quality and process control on a meaningfully larger scale.

The facilities and operations meet Good Manufacturing Practices standards, and retain site licenses from Health Canada and a foreign government.

The Company is no longer bound by production limitations.

Up to 3 million capsules can be produced and 10,000 bottles can be packaged per day.

A half million dollar worth of products in retail value can be produced daily.

Up to \$7 million in possible savings can be generated in annual manufacturing costs.



Recent Developments

May 4 2018, Eastwood Bio-Medical Canada Inc. Announces Thirty-Five New Products.

June 29 2018, Eastwood Bio-Medical Canada Enters Binding Terms for Asian Exports.

August 9 2018, Eastwood Bio-Medical Canada to Acquire Production Facilities.

August 9 2018, Eastwood Bio-Medical Canada Inc. Introduces New Product for Memory and Cognitive Function in Adults.

September 5 2018, Eastwood Bio-Medical Canada Inc. Introduces New Cannabis and Cholesterol Products.

September 10 2018, Eastwood Bio-Medical Canada Inc. Announces Product Initial Shipment of Products to Korea Valuing at about \$450,000 in Consumer Retail Value.

September 24 2018, Eastwood Bio-Medical Canada Announces Eleotin® Generated \$30,000 Sept 20-24 in Asia.



Market Potential

Type 2 diabetes market is expected to more than double, to \$64 billion by 2026.

Global hypertension market will reach USD \$32 billion by the end of 2020.

The global Alzheimer's market is expected to reach \$10.4 billion in 2021.

Eleotin® Highlights*

Advertising Standards Canada (ASC) approved the flagship product, Eleotin® Bentley, to be marketed as "World's No.1 Doctor recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada."*

- World's No.1 Doctor recommended: Over 3000+ doctors.
- Over 2,500 Newspaper & Television Acclaims (including New York Times #1 Best Sellers).
- Researched/Clinically tested by Universities and Governments
- Strongly recommended by more than 4 Associations.*
- Licenses issued by 8 Government Authorities.
- Best Diabetic & Hypertension Management Drug of the Year 2010.*
- As of 2018, more than 500,000 Users, and over 2,000 YouTube testimonials.



Eleotin® Comparison Chart*

	Pharmaceutical Drugs	Other Herbal Products	Traditional Chinese Medicine	Folkloric Treatments/Alternative Treatments	Eleotin®*
Modes of Actions (How it Works)	Known – Can be used with other Pharmaceutical Drugs	Unknown – Unsafe when used with pharmaceutical Drugs	Unknown – Unsafe when used with pharmaceutical Drugs	Unknown – Unsafe when used with pharmaceutical Drugs	Known – Can be safely used with other Pharmaceutical Drugs*
Long Term Effect	None	None	Unknown	None	Semi-permanent efficacy*
Side Effects	Severe	Unknown Risk	Relatively safe	Unknown Risk	Proven to be safe*
Price	Relatively Cheap	Expensive	Expensive	Expensive	Affordable to Very Expensive*
Quality Control	Good	Unreliable	Mostly Unreliable (Agricultural chemicals & insecticide residues)	Unreliable	Good*
Preventative	No	No	No	No	Yes*
Convenience	Prescription Required	Prescription not required	Prescription required depending on the situation	Prescription not required	Prescription not required*
For Serious & Terminal Diabetics	No effect	Not Applicable	Not Applicable	Not Applicable	Very effective*
Overall Evaluation	Short-term and invasive treatment. Toxic and severe side effects. Resistance develops. Ever increasing dosages.	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar	Shotgun approach. Most of them rely on artificial indigestion to lower the blood sugar	Long term & safe reversal effects. General health improvements *

*Cautionary Statements and Disclaimers

This factsheet contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Eastwood Bio-Medical Canada Inc. (the Company) and the Company's affiliates, including expectations and assumptions concerning TSX Venture Exchange approvals. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Although the data found in this Fact Sheet have been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis. Changes may be periodically made to the information herein; these changes may or may not be incorporated in any new versions of this Fact Sheet. It is recommended that careful attention be paid to the contents of any information associated with a file, and that the originator

of the data or information be contacted with any questions regarding appropriate use. If you find any errors or omissions, please report them to info@eastwoodcos.com.

Notwithstanding claims or statements made by any officer, director, employee, related party, or affiliate of Eastwood Bio-Medical Canada in any form including written or verbal, EBM makes no claims regarding any products it distributes or manufactures except for the sanctioned claims referred to in slide 4 of this Fact Sheet. Readers should consider only these claims when evaluating this document. Except for the claims allowed by Health Canada Product Licenses 80000196, 80000364, 80000365, 80000477, 80000481, 80000504, 80000866, the Singapore Health Science Authority CDA (HSU) 40:43/01-B(V), the National Pharmaceutical Administration NPA (CPM) 6:06 /1 Vol. 19, the Food and Drug Administration Authority (Republic of China) 0900027995, the Food and Drug Administration Authority (Peoples Republic of China) Import Food Hygiene Supervision and Inspection Bureau Certificate 990067, the Food and Drug Administration Authority Approval Number J20060001, neither Eastwood Bio-Medical Canada Inc., its affiliated companies, its employees, its distributors, nor its personnel make any claims that the products distributed by Eastwood Bio-Medical Canada cure, diagnose, or, prevent any diseases.

Eastwood Bio-Medical Canada Inc. (EBM) is not liable for any information provided on this Fact Sheet with regard to recommendations regarding the mentioned products for any health purposes. The products or claims made about specific nutrients or products have not been evaluated by the United States Food and Drug Administration. Dietary products are not intended to treat, prevent or cure disease. Consult with a healthcare professional before starting any diet, supplement or exercise program. EBM makes no guarantee or warranty with respect to any products or services sold. EBM is not responsible for any damages for information provided by the Fact Sheet even if EBM has been advised of the possibility of damages. Statements regarding potential health benefits from taking EBM products that appear on this website have not been evaluated by the FDA, and may not have been evaluated by any other governmental body.

Based on unsolicited third party opinions from unaffiliated individuals is on their own independent research. Except for claims referred to on the above information, EBM takes no responsibility for any claims.